These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25851544)

  • 61. Genomic instability in pluripotent stem cells: implications for clinical applications.
    Peterson SE; Loring JF
    J Biol Chem; 2014 Feb; 289(8):4578-84. PubMed ID: 24362040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Conditionally replicating adenovirus prevents pluripotent stem cell-derived teratoma by specifically eliminating undifferentiated cells.
    Mitsui K; Ide K; Takayama A; Wada T; Irie R; Kosai K
    Mol Ther Methods Clin Dev; 2015; 2():15026. PubMed ID: 26269798
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Engineered micromechanical cues affecting human pluripotent stem cell regulations and fate.
    Nampe D; Tsutsui H
    J Lab Autom; 2013 Dec; 18(6):482-93. PubMed ID: 24062363
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug Targets.
    Boheler KR; Gundry RL
    Stem Cells Transl Med; 2017 Jan; 6(1):131-138. PubMed ID: 28170199
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Biobanking of human pluripotent stem cells in China.
    Stacey GN; Hao J
    Cell Prolif; 2022 Jul; 55(7):e13180. PubMed ID: 35652319
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The consequences of recurrent genetic and epigenetic variants in human pluripotent stem cells.
    Andrews PW; Barbaric I; Benvenisty N; Draper JS; Ludwig T; Merkle FT; Sato Y; Spits C; Stacey GN; Wang H; Pera MF
    Cell Stem Cell; 2022 Dec; 29(12):1624-1636. PubMed ID: 36459966
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches.
    Tegtmeyer M; Nehme R
    J Mol Biol; 2022 Feb; 434(3):167221. PubMed ID: 34474087
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities.
    Kim TW; Koo SY; Studer L
    Front Cell Dev Biol; 2020; 8():729. PubMed ID: 32903681
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Progress in the production of haematopoietic stem and progenitor cells from human pluripotent stem cells.
    Fidanza A; Forrester LM
    J Immunol Regen Med; 2021 Aug; 13():100050. PubMed ID: 34405125
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Using human pluripotent stem cell models to study autism in the era of big data.
    Nehme R; Barrett LE
    Mol Autism; 2020 Mar; 11(1):21. PubMed ID: 32293529
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Parametric analysis of colony morphology of non-labelled live human pluripotent stem cells for cell quality control.
    Kato R; Matsumoto M; Sasaki H; Joto R; Okada M; Ikeda Y; Kanie K; Suga M; Kinehara M; Yanagihara K; Liu Y; Uchio-Yamada K; Fukuda T; Kii H; Uozumi T; Honda H; Kiyota Y; Furue MK
    Sci Rep; 2016 Sep; 6():34009. PubMed ID: 27667091
    [TBL] [Abstract][Full Text] [Related]  

  • 72. hPSCs-derived Schwann cells serve for disease modeling and drug discovery.
    Erickson A; Adameyko I
    Cell Stem Cell; 2023 May; 30(5):501-502. PubMed ID: 37146574
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Harnessing the Power of Stem Cell Models to Study Shared Genetic Variants in Congenital Heart Diseases and Neurodevelopmental Disorders.
    Chang X; Gu M; Tchieu J
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159270
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tumorigenicity Assessment of Human Cancer Cell Lines Xenografted on Immunodeficient Mice as Positive Controls of Tumorigenicity Testing.
    Oh S; Gu EY; Han JS; Lee BS; Moon KS; Kim YB; Han KH
    Int J Toxicol; 2022 Dec; 41(6):476-487. PubMed ID: 36069520
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Micro/nanoengineered technologies for human pluripotent stem cells maintenance and differentiation.
    Esfahani SN; Resto Irizarry AM; Xue X; Lee SB; Shao Y; Fu J
    Nano Today; 2021 Dec; 41():. PubMed ID: 34745321
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Helping Induced hPSCs Clean Up Their Act.
    Jeong HC; Cha HJ
    Cell Chem Biol; 2017 Jun; 24(6):651-652. PubMed ID: 28644953
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.
    Stacey GN; Cao J; Hu B; Zhou Q
    Cell Prolif; 2022 Aug; 55(8):e13301. PubMed ID: 35933704
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A scalable and tunable thermoreversible polymer for 3D human pluripotent stem cell biomanufacturing.
    Johnson HJ; Chakraborty S; Muckom RJ; Balsara NP; Schaffer DV
    iScience; 2022 Oct; 25(10):104971. PubMed ID: 36147944
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genome-wide Screen for Culture Adaptation and Tumorigenicity-Related Genes in Human Pluripotent Stem Cells.
    Weissbein U; Peretz M; Plotnik O; Yanuka O; Sagi I; Golan-Lev T; Benvenisty N
    iScience; 2019 Jan; 11():398-408. PubMed ID: 30660107
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin.
    Haramoto Y; Onuma Y; Mawaribuchi S; Nakajima Y; Aiki Y; Higuchi K; Shimizu M; Tateno H; Hirabayashi J; Ito Y
    Regen Ther; 2020 Jun; 14():306-314. PubMed ID: 32462059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.